title: [Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].
abstract: OBJECTIVE
  To evaluate the safety and efficacy of Firebird drug-eluting stent (DES) combining Tirofiban and Cypher DES combining Tirofiban in patients with acute coronary syndrome (ACS).
  
  
  METHODS
  323 ACS patients were divided into 2 general conditions-matched groups: Firebird group (n = 161) undergoing Firebird DES implantation and Tirofiban intravenous injection 10 microg x kg(-1) within 3 minutes followed by Tirofiban 0.15 microg x kg(-1) x min(-1) intravenous maintenance infusion with micro pump for 36 hours, and Cypher group (n = 162) undergoing Cypher DES implantation and Tirofiban. The safety was observed instantly and 36 h after the implantation. The patients were followed up for 30 d. Some patients in the Firebird group underwent coronary angiography and intravascular ultrasound because of angina and part of target vessels underwent revascularization.
  
  
  RESULTS
  There were no significant differences between the 2 groups in ejection fraction target coronary lesion type, blood platelet count, HB and HCT before treatment. The success rates of operation were both 100% in these 2 groups. No complication occurred in both groups. There were not significant differences in the blood platelet count, hemoglobin, hematocrit, acute stent thrombosis rate (1.2% vs 1.2%), acute myocardial infarction rate (1.3% vs 1.3%), target vessel revascularization rate (0.6% vs 1.3%), and rehospitalization rate (1.3% vs 0.7%) (all P > 0.05). 30 d no in-stent restenosis was found by angiographic and intravascular ultrasound follow-up in the Firebird group.
  
  
  CONCLUSIONS
  Firebird DES combining Tirofiban and Cypher DES combining Tirofiban are both safe and effective in treating ACS.
authors.affiliation: Department of Cardiology, First Clinical Medical College of Harbin Medical University, Harbin 150001, China.
authors.forename: Yu-juan
authors.initials: YJ
authors.lastname: Zhao
authors.forename: Li-jun
authors.initials: LJ
authors.lastname: Zhou
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Li
authors.forename: Pi-dong
authors.initials: PD
authors.lastname: Liu
authors.forename: Yan-dong
authors.initials: YD
authors.lastname: Chen
authors.forename: Li-yun
authors.initials: LY
authors.lastname: Song
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D014443:Tyrosine; D000077466:Tirofiban